LABP-104

NIMML Institute and NImmune Biopharma have published case studies demonstrating how their TITAN-X AI platform has successfully identified novel therapeutic targets and accelerated drug development for inflammatory and autoimmune diseases.

The NIMML Institute and NImmune Biopharma have published positive Phase 1 clinical results for NIM-1324, a novel oral treatment for Systemic Lupus Erythematosus (SLE), showing it to be safe and well-tolerated with no dose-limiting toxicities.

NIM-1324, an orally administered LANCL2 agonist, demonstrates therapeutic efficacy in three mouse models of lupus, supporting its potential to induce immune tolerance.

NImmune Biopharma announced positive Phase 1 clinical results for NIM-1324, a novel therapeutic for systemic lupus erythematosus (SLE), at the American College of Rheumatology's annual meeting. The results demonstrated safety, tolerability, and potential as a first-in-class precision therapeutic for SLE.